ArticleBioMed research international2026
Ameliorative Effects of Nypa fruticans Leaf Extract on Anxiety and Depression: Evidence From In Vivo and In Silico Studies.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ameliorative Effects of Nypa fruticans Leaf Extract on Anxiety and Depression: Evidence From In Vivo and In Silico Studies.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ethnopharmacological relevanceNypa fruticans (Arecaceae) has long been used in traditional medicine for the management of anxiety, insomnia, and depressive symptoms. However, scientific validation of its neuropharmacological activities and active constituents is limited. AIM OF THE STUDY: This study evaluated the anxiolytic, antidepressant, and sedative activities of the ethyl acetate fraction of Nypa fruticans (NF) leaves (EaNFL) through in vivo behavioral models and in silico molecular docking (MD) and molecular dynamics simulations (MDS) to provide scientific support for its traditional CNS use. MATERIALS AND
methodsNeuropharmacological activities of EaNFL were assessed in mice using elevated plus maze (EPM), hole board test (HBT), open field test (OFT), hole cross test (HCT), tail suspension test (TST), and forced swimming test (FST). Major phytochemicals identified from EaNFL were subjected to MD analysis against voltage-gated potassium channels (PDB: 4UUJ), GABA-A receptors (PDB: 6X3X), and human serotonin transporter (PDB: 5I6X). Top-binding compounds were further analyzed using MDS to assess receptor-ligand stability.
resultsEaNFL (400 mg/kg) showed significant anxiolytic activity in EPM and HBT, dose-dependent sedative properties in HCT and OFT, and notable antidepressant-like effects in TST and FST. However, reduced locomotor activity may have contributed to some of the observed behavioral outcomes. MD revealed that myricetin (CID 5281672) and quercetin (CID 5280343) predicted stable interactions and favorable binding affinities with major CNS-related receptors, as suggested by MDS analysis. Additionally, (-)-epicatechin (CID 72276) and rosmarinic acid (CID 5281792) exhibited favorable receptor interactions, suggesting therapeutic potential in anxiety, insomnia, and depression.
conclusionsEaNFL possesses notable anxiolytic, sedative, and antidepressant-like effects, supporting its traditional use in CNS disorders. MD and MDS findings suggest that myricetin, quercetin, and (-)-epicatechin acid may be key bioactive constituents underlying these effects. Further studies are warranted to elucidate molecular mechanisms and explore its pharmaceutical potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.